An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Veracyte, Inc.
VERDICT
The label
Markup
read at $59.13
Veracyte, Inc. holds its Markup at $59.13.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 15 days
Price
$59.13
Valuation
54.75 trailing · 30.94 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.93
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$59.13
54.75 P/E · 30.94 fwd
Our fair value
$48.52
18% premium
Analyst target (avg)
$55.00
-7% to current
Target low $45.00Analyst target rangeTarget high $70.00
▲ current $59.13 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$59.13
you are here
Conservative
$40.50
-32%
Analyst avg
$55.00
-7%
Our fair value
$48.52
-18%
Analyst high
$70.00
+18%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the Street see limited upside at this price.
Revenue growth
21.50%
Profit margin
16.25%
Debt to equity
2.93
Analyst consensus
Buy · 11 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Diagnostics priced for perfection it cannot deliver
A patient waits for a genomic test result that could change everything, yet the real question is whether the company behind it can ever justify its current price tag. Veracyte trades at $59 against our fair value of $48.52, a margin of safety that sits at minus 18 percent. With a forward multiple of 30.9 times earnings, revenue growth of 22 percent and a profit margin of 16 percent look respectable on paper, yet they sit alongside a modest 7 percent return on equity and an unknown moat. We pass.
The business offers Afirma and Decipher classifiers that help doctors decide on thyroid and prostate cancers. Eleven analysts still carry a buy rating with a median target of $55. Those targets sit below the current quote, and the ethical screen clears without issue. None of that closes the gap between what the market is asking and what the cash flows appear able to support.
High multiples on a company with single-digit returns on equity often signal that growth must keep accelerating just to stand still. Any slowdown in test adoption or reimbursement pressure would expose that gap quickly. Currency moves and competitive shifts in diagnostics add further uncertainty. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in VCYT's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
VCYT trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 73%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $47. Entered 2026-07-18 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-18Markup$47.33+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 73%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it buy, with a mean price target of $47.
2026-07-03Markup$47.33+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$47.33Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$39.70
+21.3%
·
$1,213
+21.3%
2 months
$31.09
+54.9%
·
$1,549
+54.9%
3 months
$30.93
+55.7%
·
$1,557
+55.7%
6 months
$42.22
+14.1%
·
$1,141
+14.1%
1 year
$27.88
+72.8%
·
$1,728
+72.8%
2 years
$20.88
+130.7%
·
$2,307
+130.7%
3 years
$25.84
+86.4%
·
$1,864
+86.4%
5 years
$36.14
+33.3%
·
$1,333
+33.3%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever VCYT does next, these words stay.
Veracyte, Inc. · VCYT · Markup · $59.13
Recorded 2026-07-19 · before the outcome · scored mechanically
